On December 11th, Bristol Myers Squibb announced that the Phase III study CheckMate-8HW, a clinical study evaluating the combination of nivolumab and ipilimumab, compared the chemotherapy regimen chosen by researchers for first-line treatment of metastatic colorectal cancer (mCRC) with microsatellite highly unstable (MSI-H) or mismatch repair gene deficiency (dMMR) phenotypes, will be conducted in a pre specified midterm analysis, One of the dual primary endpoints, progression free survival (PFS), was achieved through blind independent center review (BICR) assessment.